ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2016
Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- In Silico Assessment of Potential Geroprotectors: From Separate Endpoints to Complex Pharmacotherapeutic Effects.International journal of molecular sciences · 2025Article
- Multimodal Diagnostic Approaches to Advance Precision Medicine in Sarcopenia and Frailty.Nutrients · 2022Review
- Research in metabolic ageing - a tale of mice versus humans?Nature reviews. Endocrinology · 2022Article
- Study of Longitudinal Aging in Mice: Presentation of Experimental Techniques.The journals of gerontology. Series A, Biological sciences and medical sciences · 2021Article
- Directly Reprogrammed Human Neurons to Understand Age-Related Energy Metabolism Impairment and Mitochondrial Dysfunction in Healthy Aging and Neurodegeneration.Oxidative medicine and cellular longevity · 2021Review
- Aging and immunotherapies: New horizons for the golden ages.Aging and cancer · 2020Article
- Reducing Senescent Cell Burden in Aging and Disease.Trends in molecular medicine · 2020Review
- Discovery, development, and future application of senolytics: theories and predictions.The FEBS journal · 2020Review
- Creating the Next Generation of Translational Geroscientists.Journal of the American Geriatrics Society · 2019Article
- Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging.Redox biology · 2018Article
- Circulating levels of monocyte chemoattractant protein-1 as a potential measure of biological age in mice and frailty in humans.Aging cell · 2018Article
- Nutrition, metabolism, and targeting aging in nonhuman primates.Ageing research reviews · 2017Review
- The Clinical Potential of Senolytic Drugs.Journal of the American Geriatrics Society · 2017Article
- Cellular Senescence: A Translational Perspective.EBioMedicine · 2017Review
- A Frailty Index Based On Deficit Accumulation Quantifies Mortality Risk in Humans and in Mice.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Through the progress of basic science research, fundamental mechanisms that contribute to age-related decline are being described with increasing depth and detail. Although these efforts have identified new drug targets and compounds that extend life span in model organisms, clinical trials of therapeutics that target aging processes remain scarce. Progress in aging research is hindered by barriers associated with the translation of basic science discoveries into the clinic. This report summarizes discussions held at a 2014 Geroscience Network retreat focused on identifying hurdles that currently impede the preclinical development of drugs targeting fundamental aging processes. From these discussions, it was evident that aging researchers have varied perceptions of the ideal preclinical pipeline. To forge a clear and cohesive path forward, several areas of controversy must first be resolved and new tools developed. Here, we focus on five key issues in preclinical drug development (drug discovery, lead compound development, translational preclinical biomarkers, funding, and integration between researchers and clinicians), expanding upon discussions held at the Geroscience Retreat and suggesting areas for further research. By bringing these findings to the attention of the aging research community, we hope to lay the foundation for a concerted preclinical drug development pipeline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.